Efient prasugrel regulatory update

The U.K.’s NICE issued updated draft guidance recommending the use of Efient prasugrel from Eli Lilly in combination with aspirin to prevent atherothrombotic events in adults with acute coronary syndrome (ACS) or ST-segment elevation myocardial infarction (STEMI) having primary or delayed percutaneous coronary intervention (PCI) -- its approved indication. In 2009, the committee issued guidance recommending the use of the purinergic receptor P2Y G protein-coupled 12 ( P2RY12; P2Y12) antagonist in combination with aspirin to prevent atherothrombotic events in ACS patients undergoing PCI only when immediate primary PCI for STEMI is necessary, when stent thrombosis has occurred during Plavix clopidogrel use or in patients with Type II diabetes. The updated guidance assessed the clinical and cost effectiveness of Efient and noted that since 2009, NICE has published guidance on the use of Brilique ticagrelor from The Medicines Co. (NASDAQ:MDCO, Parsippany, N.J.) and AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) for the same indication and generics of Plavix have become available. ...